Precision Bio gains on early Phase 1 data for Hep B candidate
Precision BioSciences (NASDAQ:DTIL) added ~6% in the premarket on Wednesday after the gene therapy developer announced initial safety and efficacy data from an early-stage trial for its Hepatitis B ...
pharmaphorum6d
The irony of data in precision medicine: Igniting progress while creating challenges
This is very fertile ground for precision medicine discoveries and breakthroughs. However, single cells result in huge data, with these big unstructured data volumes often ending up in bespoke ...
Hosted on MSN1mon
Precision Bio rises after gene editing data: BMO upgrades (update)
According to data from DTIL's OTC-HOPE study, the first male infant treated with ECUR-506 had a normal mean ammonia level among other responses following a single dose of Precision Bio's (NASDAQ ...
Nature1y
Powering the future of precision oncology medicine with big data
The most impactful medicines of the future will have leveraged data at an unprecedented scale and infused precision medicine from the earliest stages of drug development,” said Brian Lamon ...